Literature DB >> 12594954

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

Dhaya Seshasayee1, Patricia Valdez, Minhong Yan, Vishva M Dixit, Daniel Tumas, Iqbal S Grewal.   

Abstract

BLys , a key cytokine that sustains B cell maturation and tolerance, binds three receptors: BR3, BCMA, and TACI. Results from knockout mice implicate a major functional role for BR3 and a redundant one for BCMA in B cell function. TACI's role is controversial based on defects in TI antibody responses accompanied by B cell hyperplasia in knockout mice. We have presently characterized a precise role for TACI in vivo. TACI(-/-) mice develop fatal autoimmune glomerulonephritis, proteinurea, and elevated levels of circulating autoantibodies. Treatment of B cells with TACI agonistic antibodies inhibits proliferation in vitro and activation of a chimeric receptor containing the TACI intracellular domain induces apoptosis. These results demonstrate the critical requirement for TACI in regulating B cell homeostasis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594954     DOI: 10.1016/s1074-7613(03)00025-6

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  111 in total

1.  Impaired IgA class switching in APRIL-deficient mice.

Authors:  Emanuela Castigli; Sumi Scott; Fatma Dedeoglu; Paul Bryce; Haifa Jabara; Atul K Bhan; Emiko Mizoguchi; Raif S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-26       Impact factor: 11.205

Review 2.  Genetics of SLE in mice.

Authors:  Dwight H Kono; Argyrios N Theofilopoulos
Journal:  Springer Semin Immunopathol       Date:  2006-09-14

3.  Early preplasma cells define a tolerance checkpoint for autoreactive B cells.

Authors:  Donna A Culton; Brian P O'Conner; Kara L Conway; Ramiro Diz; Jennifer Rutan; Barbara J Vilen; Stephen H Clarke
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

Review 4.  The rationale for BAFF inhibition in systemic lupus erythematosus.

Authors:  Anne Davidson
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

5.  A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.

Authors:  Yulia Vugmeyster; Dhaya Seshasayee; Wesley Chang; Anahid Storn; Kathy Howell; Susan Sa; Tenea Nelson; Flavius Martin; Iqbal Grewal; Ellen Gilkerson; Ben Wu; Jeff Thompson; Barbara N Ehrenfels; Song Ren; An Song; Thomas R Gelzleichter; Dimitry M Danilenko
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

6.  Identification of a novel immunosubversion mechanism mediated by a virologue of the B-lymphocyte receptor TACI.

Authors:  Jason R Grant; Alexander R Moise; Wilfred A Jefferies
Journal:  Clin Vaccine Immunol       Date:  2007-05-30

Review 7.  Common variable immune deficiency: reviews, continued puzzles, and a new registry.

Authors:  Charlotte Cunningham-Rundles; Adina Kay Knight
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

8.  Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.

Authors:  Li Zhang; Lin Radigan; Ulrich Salzer; Timothy W Behrens; Bodo Grimbacher; George Diaz; James Bussel; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2007-11       Impact factor: 10.793

Review 9.  [Atacicept: a new B lymphocyte-targeted therapy for multiple sclerosis].

Authors:  H-P Hartung
Journal:  Nervenarzt       Date:  2009-12       Impact factor: 1.214

10.  The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function.

Authors:  John J Lee; Ingrid Rauter; Lilit Garibyan; Esra Ozcan; Tatyana Sannikova; Stacey R Dillon; Anthony C Cruz; Richard M Siegel; Richard Bram; Haifa Jabara; Raif S Geha
Journal:  Blood       Date:  2009-07-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.